Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The protocol, approved by the Medical Research Council, was issued to assess the safety and efficacy of the non-surgical device for applying it to the national scale up of adult male circumcision in Zimbabwe
Models show that to have the highest impact on the HIV epidemic, circumcision of up to 80% of men in high prevalence countries, where MC rates are low, needs to be achieved (UNAIDS 2009; Manicaland HIV/STD Prevention Project, 2008; Bollinger, et al, 2009). Hallett and colleagues in 2008 showed that for Zimbabwe specifically, HIV incidence could be reduced between 25% to 35% if about 50% of men are circumcised. All modelings conducted show that MC programs must be part of a comprehensive HIV prevention package as MC alone will not tip the HIV epidemic into a terminal decline.
The PrePex Device offers hope for rapid scale up of adult male circumcision in resource limited settings.
Once the safety and efficacy have been established, it is important to conduct operations research to determine how best to implement both device and surgical circumcisions in the national program. Thus, the Zimbabwe MOHCW is planning a three phase trial in order to determine the safety of the PrePexTM device, its performance and the ease of use in an implementation roll out.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental: PrePexâ„¢ device | Experimental | Adult male circumcision by the PrePexâ„¢ device |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PrePexâ„¢ device | Device | PrePexâ„¢ device for adult male circumcision. The non-surgical PrePexâ„¢ device with No Injected Anesthesia |
|
| Measure | Description | Time Frame |
|---|---|---|
| The Safety and Efficacy of the PrePex Device for adult male circumcision in Zimbabwe | Outcome measures include: Clinical adverse events and device-related incidents | 8 week post-procedure follow up appointment and examination |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluating the procedure duration | The total procedure and preparation time of the PrePexâ„¢ device circumcision procedure | 8 week post-procedure follow up appointment and examination |
| Evaluating the pain at key time points |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gerald Gwinji, MBChB, MPH | PS- MoHCW | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Znfpc Spilhaus Center | Harare | Zimbabwe |
Not provided
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D015229 | Sexually Transmitted Diseases, Viral |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Pain assessment at key time points using Visual Analog Scale (VAS)
| 8 week post-procedure follow up appointment and examination |
| Evaluating the discomfort during daily activities | using questionnaires | 8 week post-procedure follow up appointment and examination |
| Evaluating the compliance during use (with follow-up) | compliance during use (with follow-up)using questionnaires | 8 week post-procedure follow up appointment and examination |
| Evaluating the procedure acceptability by Doctors | procedure acceptability by Doctors using questionnaires | 8 week post-procedure follow up appointment and examination |
| Glans fully exposed | 8 week post-procedure follow up appointment and examination |
| Evaluating time to complete healing | time to complete healing using wound assessment | 8 week post-procedure follow up appointment and examination |
| Evaluating the cosmetic results | 8 week post-procedure follow up appointment and examination |
| Procedure acceptability by Nurses | Procedure acceptability by Nurses using questionnaires | 8 week post-procedure follow up appointment and examination |
| Satisfaction by subjects | Satisfaction by subjects | 8 week post-procedure follow up appointment and examination |
| Satisfaction by providers | using questionnaires | 8 week post-procedure follow up appointment and examination |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |